At close: 4:00:01 PM EST
After hours: 4:20:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
886.00
2,329.00
18,739.00
--
Operating Expense
195,067.00
129,450.00
87,110.00
84,388.00
81,481.00
Operating Income
-195,067.00
-128,564.00
-84,781.00
-65,649.00
-81,481.00
Net Non Operating Interest Income Expense
19,662.00
6,147.00
837.00
111.00
593.00
Other Income Expense
-39,447.00
-216,399.00
-7.00
-122.00
-5.00
Pretax Income
-214,852.00
-338,816.00
-83,951.00
-65,660.00
-80,893.00
Tax Provision
50.00
-26.00
-136.00
141.00
--
Net Income Common Stockholders
-214,902.00
-338,790.00
-83,815.00
-65,801.00
-80,893.00
Diluted NI Available to Com Stockholders
-214,902.00
-338,790.00
-83,815.00
-65,801.00
-80,893.00
Basic EPS
17.02
-49.12
-24.75
-25.00
-38.00
Diluted EPS
17.02
-49.12
-24.75
-25.00
-38.00
Basic Average Shares
37,123.72
6,897.07
3,371.23
2,629.78
2,134.87
Diluted Average Shares
37,123.72
6,897.07
3,371.23
2,629.78
2,134.87
Total Operating Income as Reported
-193,227.00
-242,303.00
-84,781.00
-65,649.00
-81,481.00
Total Expenses
195,067.00
129,450.00
87,110.00
84,388.00
81,481.00
Net Income from Continuing & Discontinued Operation
-214,902.00
-338,790.00
-83,815.00
-65,801.00
-80,893.00
Normalized Income
-216,355.60
-141,536.14
-83,815.00
-65,801.00
-80,893.00
Interest Income
19,662.00
6,147.00
837.00
111.00
593.00
Net Interest Income
19,662.00
6,147.00
837.00
111.00
593.00
EBIT
-195,067.00
-128,564.00
-84,781.00
-65,649.00
-81,481.00
EBITDA
-195,067.00
-127,820.00
-83,214.00
-64,073.00
-80,485.00
Reconciled Depreciation
-220.00
744.00
1,567.00
1,576.00
996.00
Net Income from Continuing Operation Net Minority Interest
-214,902.00
-338,790.00
-83,815.00
-65,801.00
-80,893.00
Total Unusual Items Excluding Goodwill
1,840.00
-197,269.00
--
--
--
Total Unusual Items
1,840.00
-197,269.00
--
--
--
Normalized EBITDA
-196,907.00
69,449.00
-83,214.00
-64,073.00
-80,485.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
386.40
-15.14
--
--
--
12/31/2020 - 4/7/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ORKA Oruka Therapeutics, Inc.
20.31
-2.17%
APGE Apogee Therapeutics, Inc.
47.71
+1.47%
DNTH Dianthus Therapeutics, Inc.
23.80
+3.30%
IRON Disc Medicine, Inc.
64.50
+2.46%
ANAB AnaptysBio, Inc.
14.55
-3.00%
FHTX Foghorn Therapeutics Inc.
5.14
+3.21%
UPB Upstream Bio, Inc.
16.21
-2.41%
IDYA IDEAYA Biosciences, Inc.
25.61
+3.31%
STOK Stoke Therapeutics, Inc.
11.68
+3.36%
ACLX Arcellx, Inc.
75.54
+0.44%